Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

9 results
5:14 PM, Feb 07, 2014  |  BC Extra | Clinical News

ADX71149 misses in Phase IIa for anxious depression

in Phase IIa testing for schizophrenia. The compound is a positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2
mGluR2 ). In 2005, Addex and Janssen partnered to discover, develop and commercialize worldwide mGluR2
4:35 PM, Aug 09, 2013  |  BC Extra | Financial News

Addex raises CHF3.2 million

with Johnson & Johnson (NYSE:JNJ) to discover, develop and commercialize positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 2
mGluR2 ). Phase II depression data for ADX71149 , the lead compound in the program …
6:14 PM, Oct 12, 2012  |  BC Extra | Financial News

Addex raises CHF9.6 million

of metabotropic glutamate receptor subtype 5 (mGluR5), and ADX71149 is a positive allosteric modulator of mGluR2
6:04 PM, Aug 29, 2012  |  BC Extra | Clinical News

Lilly drops mGluR2/3 agonist after schizophrenia misses

as a result of the discontinuation. The product is an oral prodrug of LY404039, a metabotropic glutamate receptor subtype 2
5:57 PM, Jul 11, 2012  |  BC Extra | Clinical News

Lilly's schizophrenia product misses Phase IIb endpoints

risperidone met the co-primary endpoints vs. placebo. Pomaglumetad methionil is a prodrug of LY404039, a metabotropic glutamate receptor subtype 2
3 ( mGluR2 /3) agonist. The trial is the first of two trials intended to support …
4:53 PM, Apr 13, 2012  |  BC Extra | Company News

Addex restructuring

glutamate receptor subtype 5 ( mGluR5 ), and ADX71149 is a positive allosteric modulator of mGluR2
5:40 PM, Jul 07, 2011  |  BC Extra | Company News

Addex restructuring

testing to Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 , a positive allosteric modulator of mGluR2
6:14 PM, Sep 15, 2010  |  BC Extra | Financial News

Addex raises CHF20 million

dyskinesia in Parkinson's disease (PD) patients; and ADX71149 , a positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2
mGluR2 ) in Phase I testing to treat schizophrenia, anxiety and other indications. ADX71149 is …
6:06 PM, Sep 04, 2007  |  BC Extra | Clinical News

LY2140023 meets Phase II schizophrenia endpoint

The double-blind, Russian trial enrolled 196 patients. LY2140023 is an oral prodrug of LY404039, a metabotropic glutamate receptor subtype 2